Company Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.
Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 709 |
| CEO | Chad Robins |
Contact Details
Address: 1165 Eastlake Avenue East Seattle, Washington 98109 United States | |
| Phone | 206 659 0067 |
| Website | adaptivebiotech.com |
Stock Details
| Ticker Symbol | ADPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001478320 |
| CUSIP Number | 00650F109 |
| ISIN Number | US00650F1093 |
| Employer ID | 27-0907024 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chad M. Robins M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Julie Rubinstein | President and Chief Operating Officer |
| Dr. Harlan S. Robins Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Christopher Carlson Ph.D. | Founder |
| Kyle Piskel | Vice President, Chief Financial Officer and Principal Accounting Officer |
| Karina Calzadilla | Vice President of Investor Relations |
| Francis T. Lo | Chief People Officer |
| Susan Bobulsky | Chief Commercial Officer of MRD |
| Mary Pat Lancelotta | Senior Vice President of MRD BioPharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 22, 2024 | 144 | Filing |